Scleroderma in Children: A Guide for Outpatient Pediatricians

Introduction

Scleroderma in children is a rare type of pediatric rheumatic illness, consisting of two main forms: localized scleroderma (morphea) and juvenile systemic sclerosis (jSSc). Localized scleroderma primarily affects the skin and subcutaneous tissues, sometimes leading to orthopedic or neurological issues, but it does not progress to systemic disease or impact internal organs. In contrast, juvenile systemic sclerosis is characterized by skin thickening and involvement of internal organs, such as the gastrointestinal, pulmonary, cardiac, and renal systems, akin to adult systemic sclerosis. Both forms can result in significant health issues, ranging from growth defects and contractures in localized cases to serious organ complications in systemic ones. Early detection and referral are crucial since diagnosis delays are common and heighten the risk of permanent damage. This review discusses the indicators for suspecting pediatric scleroderma, essential differential diagnoses, and diagnostic challenges, the typical diagnostic journey for patients, and the appropriate timing for involving pediatric rheumatology. It also emphasizes current consensus guidelines, such as the PReS/SHARE initiatives from Europe, and practical advice for primary care providers in Central Europe and beyond.

When to Consider This Diagnosis

Outpatient pediatricians should maintain a high level of suspicion for scleroderma in any child exhibiting unexplained skin induration, pigmentary changes, or Raynaud’s phenomenon, mainly when the findings are progressive or accompanied by other symptoms. Key clinical scenarios include:

Localized scleroderma (Morphea): Observe the child displaying one or more patches of skin that appear thickened, hardened, or discolored. Early-stage lesions typically manifest as red or purple spots that develop into shiny, ivory sclerotic plaques with purple borders. Common forms include a single oval morphea plaque on the trunk or limb or a linear sclerotic streak on an extremity. A notable example is linear scleroderma on the forehead or scalp, known as the “en coup de sabre” lesion, which looks like a linear depression or scar-like band. Initially, such lesions may be confused with birthmarks, bruises, or fungal infections, yet any noticeable tightening or atrophy of the skin and underlying tissue signals a concern. Any persistent, growing, or hardened skin lesion in a child—especially those with a light center and darkened rim—should raise suspicion of morphea.

Juvenile systemic sclerosis (jSSc): Consider systemic sclerosis in a child (commonly of school age or adolescence) who displays Raynaud’s phenomenon (episodic finger blanching or cyanosis in cold conditions) along with other indicative symptoms. Initial signs of jSSc can be subtle: children may show puffy or swollen fingers that evolve into sclerodactyly (skin tightening of the fingers) and diminished skin folds. They might experience tight skin on the hands or face (e.g., difficulty making a fist or a constricted feeling around the mouth). Skin alterations are typically symmetrical and can begin acrally (on hands and feet) before progressing to the arms, legs, or trunk over time. In certain cases, non-dermatologic indicators may appear before evident skin thickening; for instance, unexplained changes in nailfold capillaries (dilated or drop-out capillaries observed under microscopy), digital tip ulcers, or pitting scars, as well as unexplained dyspnea or dysphagia in a child with Raynaud’s, should heighten suspicion for systemic sclerosis. Given that jSSc is extremely rare (with an annual incidence of approximately 0.27 per million children), these manifestations are often initially assigned to other conditions; however, persistent Raynaud’s accompanied by any additional autoimmune features (such as swollen fingers, arthralgias, GERD, etc.) requires assessment for juvenile systemic sclerosis.

Table 1: Common Subtypes of Pediatric Scleroderma and Key Features

Subtype & Category	Typical Presentation and Features	Key Considerations for Pediatricians
Plaque Morphea (localized)	One or several oval or round patches on the trunk/limbs. Active lesions have a red or purple inflammatory border and an ivory center that becomes firm/thick. Later, hyperpigmented or hypopigmented scarring and skin thinning occur.	Confined to the skin (no internal organ involvement). It can cause cosmetic distress. If lesions are enlarging or crossing joints, refer for treatment to prevent contractures. A biopsy can confirm but is often not required if classic features are present.
Linear Scleroderma (localized)	A linear band of sclerotic skin, usually on an extremity (running down an arm/leg) or on the face/scalp (“en coup de sabre”). Skin is hard, bound down in a streak, often with pigment changes. On the face, it may cause a visible indent or scar from the forehead into the scalp.	Highest morbidity among localized subtypes. Linear lesions on limbs can involve underlying fascia, muscle, or bone, leading to limb length discrepancy or joint contractures. Facial linear lesions may be associated with hemifacial atrophy, dental malocclusion, eye involvement (uveitis), or CNS involvement (seizures). Early systemic therapy is needed to limit the damage.
Generalized Morphea (localized)	Multiple morphea plaques across broad body areas or coalesce into large patches. Often, the trunk and proximal limbs can involve all skin layers.	Widespread skin involvement can restrict mobility (due to stiffness) and cause significant cosmetic impact. No internal organ fibrosis, but extensive skin disease warrants systemic treatment (e.g., methotrexate) similar to linear scleroderma.
Deep Morphea / Pansclerotic (localized)	The rare, extensive form of morphea where fibrosis extends through the dermis into subcutaneous fat, fascia, muscle, and bone. Pansclerotic morphea can encase an entire limb circumferentially.	It can be a woody induration of an entire limb or torso segment. High risk of ulcers, infections, and joint immobilization. No internal organ involvement but functionally devastating – urgent referral needed. Often requires aggressive immunosuppression; physical therapy is essential to preserve range of motion.
Juvenile Systemic Sclerosis (jSSc) – Limited cutaneous	Skin thickening is limited to areas distal to elbows and knees (hands, forearms, lower legs, face). It often starts with Raynaud’s gradual tightening of finger skin (sclerodactyly) and facial changes (perioral skin tightening causing a small mouth).	“Limited” refers to skin distribution, but internal organ involvement can still occur (e.g., pulmonary arterial hypertension or GI dysmotility). Onset may be insidious. Monitor for digital ulcers, telangiectasias, calcinosis. Regular screening of the lung (PFTs, echocardiogram) is recommended even in limited jSSc.
Juvenile Systemic Sclerosis – Diffuse cutaneous	Skin sclerosis extends proximal to elbows or knees (trunk, upper arms, thighs), often with rapid onset and progression. Raynaud’s phenomenon is usually present (though in pediatric cases, skin changes can precede Raynaud’s ~25% of the time ). Tendon friction rubs, arthritis, and carpal tunnel symptoms may occur due to deeper fibrosis.	Diffuse jSSc indicates a higher risk of severe internal organ involvement (especially interstitial lung disease). Early organ screening is imperative (HRCT of lungs, echocardiogram, renal monitoring). If diffuse skin changes are noted, aggressive immunosuppressive therapy (e.g., IV cyclophosphamide for lung fibrosis) and an urgent rheumatology referral are often warranted.
Overlap Syndrome (jSSc overlap)	jSSc features plus features of another connective tissue disease (e.g., dermatomyositis muscle weakness/rash, lupus-like antibodies, arthritis beyond what scleroderma causes). Children more often have overlapping presentations than adults.	Overlap can complicate recognition (e.g., predominant muscle inflammation might distract from evolving scleroderma). Consider jSSc overlap if a child with another rheumatic diagnosis (JDM, SLE, MCTD, etc.) develops skin tightening or Raynaud’s. Such patients need multidisciplinary management (rheumatology, dermatology, etc.).

When to suspect scleroderma: key take-home points – Any child with an indurated skin lesion that is enlarging or causing stiffness should be evaluated for localized scleroderma. Any child with Raynaud’s phenomenon plus additional cutaneous changes (or unexplained systemic symptoms like dysphagia, chronic cough, or growth failure) should be evaluated for possible systemic sclerosis. Clinical “red flags” include a shiny, tight skin patch with loss of hair or sweat in that area, a linear scar-like mark of unknown cause, unilateral face atrophy, chronic unexplained ulcers on fingertips, or persistent digital color changes. In these scenarios, do not attribute the findings to common benign causes alone – scleroderma should be on the differential and appropriate next steps (investigation or referral) taken.

Differential Diagnosis

Distinguishing scleroderma from other conditions can be challenging in the early stages. A careful history and exam, supported by selective tests or biopsy, can help differentiate. Important differentials include:

Localized scleroderma differentials: Early morphea patches (especially plaque-type) can resemble other dermatologic conditions. Lichen sclerosus (particularly genital or extragenital) causes white, atrophic patches but typically presents with a wrinkled surface and intense itching; morphea lesions are usually thicker and less pruritic, and morphea on the trunk or extremities often displays the classic violaceous border. Granuloma annulare (GA) can form ring-shaped firm bumps that might be confused with morphea’s active border. Still, GA typically presents with multiple small papules in an annular arrangement and lacks a sclerotic center. Erythema chronicum migrans (Lyme disease rash) can also manifest as an expanding ring with central clearing – in endemic areas, Lyme should be ruled out if the lesion is erythematous; morphea tends to become ivory or hyperpigmented over time rather than staying erythematous. Tinea (fungal) infection is a common misdiagnosis – a fungal plaque may exhibit scaling and a raised border, while morphea typically has a smooth, shiny surface without significant scaling. An atrophic nevus or scar (e.g., a nevus depigmentosus or a post-traumatic scar) might be mistaken for localized scleroderma and vice versa. Careful history (any prior injury?) and evolution (a congenital or long-standing static birthmark versus a lesion that appeared and enlarged over months) can help distinguish them. Linear scleroderma on the face must be differentiated from port-wine stains (capillary malformations) – port-wine stains are vascular and reddish, present from birth, and do not cause skin hardening or atrophy; by contrast, linear morphea typically appears in early childhood and progresses to a depressed, fibrotic scar with pigment changes. Parry-Romberg syndrome (progressive hemifacial atrophy) overlaps with en coup de sabre scleroderma – some experts consider these conditions related; Parry-Romberg primarily manifests as facial soft tissue atrophy without the overlying skin sclerosis, though the two conditions can coexist. If atrophy is predominant without skin thickening, Romberg syndrome (neurologist or plastic surgeon referral) is considered, but rheumatologic evaluation is often pursued due to overlap with scleroderma. Eosinophilic fasciitis (rare in children) causes limb skin and subcutaneous tissue thickening (peau d’orange texture or groove sign), often after heavy exercise – it lacks the discrete plaques of morphea, and a biopsy of the fascia confirms eosinophilic fasciitis. In summary, localized scleroderma is primarily a clinical diagnosis; a skin biopsy can assist if uncertainty remains, showing thickened collagen and inflammation, while negative fungal scrapings, the absence of scaling (ruling out eczema/psoriasis), and lesion evolution support the diagnosis of morphea over its counterparts mimics.

Systemic sclerosis differentials: Juvenile systemic sclerosis is so uncommon that more prevalent pediatric disorders are often considered first. Juvenile idiopathic arthritis (JIA)—especially the systemic or polyarticular forms—might be mistaken for scleroderma if the child experiences joint pain, contractures, or swelling of the hands. However, JIA does not cause skin tightening; if a JIA patient presents with shiny, tight skin on the fingers or face, consider the possibility of scleroderma overlap. Dermatomyositis (JDM) causes skin changes (Gottron papules, heliotrope rash) and symmetrical proximal muscle weakness. JDM skin changes are typically erythematous or violaceous (not sclerotic), but some chronic JDM patients may develop calcinosis or skin scarring. The distinguishing feature is that JDM has a classic rash distribution and elevated muscle enzymes. At the same time, juvenile systemic sclerosis (jSSc) is associated with Raynaud’s phenomenon and sclerotic skin, often with normal muscle enzymes, unless overlapping myositis exists. Mixed connective tissue disease (MCTD) and overlap syndromes in children can manifest with Raynaud’s phenomenon and some sclerodactyly alongside features of lupus or myositis; overlap is common in pediatric scleroderma. Testing for specific autoantibodies can be helpful (e.g., anti-U1 RNP in MCTD), but referral to a specialist is often necessary for nuanced distinctions. Nephrogenic systemic fibrosis (skin fibrosis associated with renal failure and gadolinium exposure) is a consideration in a child with kidney disease. However, this is exceedingly rare and usually related to dialysis contexts—a kidney failure history helps differentiate this from idiopathic jSSc. Chronic graft-versus-host disease (GVHD) following bone marrow transplant can induce scleroderma-like skin tightness. Always review the medical history: a post-transplant child with skin sclerosis is more likely to have GVHD rather than a new-onset jSSc. Scleroderma “sine scleroderma” (systemic sclerosis without skin involvement) is rare, even in adults. Nonetheless, suppose a child displays unexplained pulmonary fibrosis, pulmonary hypertension, or renal crisis with positive scleroderma-specific antibodies (such as anti-Scl-70 or anti-centromere). In that case, systemic sclerosis should be considered even if the skin has not yet been affected.

Laboratory tests can support diagnosis but are not definitive. In localized scleroderma, serologies are often negative or nonspecific—up to about 40% may have a positive ANA, yet scleroderma-specific antibodies (Scl-70, centromere) are typically absent in morphea. Therefore, a negative ANA does not rule out localized scleroderma. In juvenile systemic sclerosis (jSSc), antinuclear antibody (ANA) is usually positive (in one cohort, 100% were ANA-positive). Anti-topoisomerase I (Scl-70) seems to be the most common specific antibody in juvenile cases—interestingly, even some children with “limited” cutaneous disease had anti-Scl70, indicating high-risk serology despite milder skin. Anticentromere antibody (associated with limited cutaneous SSc in adults) is less common in children. Rheumatologic blood tests can help confirm a suspicion or identify overlapping features (e.g., extractable nuclear antigen panel, rheumatoid factor if arthritis, etc.), but normal labs do not exclude early scleroderma. Nailfold capillaroscopy (if available) is a valuable office tool: giant capillary loops or capillary dropout in a child with Raynaud’s phenomenon strongly suggests an underlying connective tissue disease (like jSSc or MCTD).

In practice, if scleroderma is considered in the differential diagnosis and the initial work-up yields no results, it’s wise to refer early to a pediatric rheumatologist or dermatologist for further evaluation, including specialized imaging or biopsy rather than conducting an extended trial of empirical treatments for presumed eczema, among other conditions. The differential diagnoses for pediatric scleroderma are extensive, but concentrating on the unique characteristics of scleroderma—such as skin hardening, fibrosis, and multi-system involvement—can assist the clinician. Table 2 (below) summarizes a few distinguishing features features:

Table 2: Selected Features Differentiating Scleroderma from Common Mimics

Condition (Mimic)	Key Differences from Scleroderma
Atopic dermatitis / Eczema	It causes itchy, scaly patches that favor flexures. No skin induration; responds to moisturizers/steroids. Morphea usually has a smooth, shiny surface without itching in older lesions.
Tinea (ringworm)	Fungal infection: annular red scaly plaques with central clearing. KOH scraping is positive for fungus. Morphea plaques lack surface scale, and KOH is negative.
Lichen sclerosus	White, shiny atrophic plaques (often genital). It can resemble morphea but is usually very pruritic and cigarette-paper texture. Biopsy can distinguish if needed. Frequently, it coexists with morphea in some patients, but lichen sclerosus lesions do not become thick or bound down.
Port-wine stain (capillary malformation)	Congenital flat vascular birthmark (pink-red), often on the face. Does not progress or cause tissue atrophy. Linear morphea en coup de sabre, by contrast, appears later in childhood and leads to a depressed, fibrotic streak with potential hair loss or brow destruction.
Juvenile Idiopathic Arthritis	Joint swelling/pain primary; no primary skin hardening. In contrast, jSSc may cause contractures due to skin fibrosis over joints rather than synovitis. If a “JIA” patient has Raynaud’s or tight skin, reassess for scleroderma overlap.
Dermatomyositis (JDM)	Muscle weakness and rash (Gottron papules, heliotrope) are hallmarks. Skin changes are erythematous, not sclerotic. JDM can cause calcinosis but not the diffuse fibrosis of SSc. Nailfold capillaries can be abnormal; however, JDM capillaries often show capillary dropout with dilations, whereas SSc can show giant loops and a different pattern.
Mixed Connective Tissue Disease	Has overlapping features (Raynaud’s, swollen hands, some sclerodactyly, plus lupus/myositis features)—often high RNP antibody. Essentially, an overlap – may progress to look like scleroderma over time. Distinguishing MCTD vs. overlap jSSc may not be critical initially, as both warrant rheumatology care.
Nephrogenic systemic fibrosis	It occurs only in patients with severe renal impairment and usually after gadolinium MRI exposure. Skin findings can mimic diffuse SSc (woody induration), but a history of kidney failure and recent contrast exposure points to NSF. Absent in those without such history.
Chronic GVHD (post-transplant)	Skin thickening in a child with a history of stem cell transplant is likely chronic graft-versus-host disease. Look for other GVHD signs (lichen planus-like changes, prior acute GVHD). Treating GVHD differs (immunosuppression overlaps, but prognosis and associations differ).

Note: In unclear situations, skin biopsies and serologic tests (such as ANA and specific antibodies) can assist but must be interpreted cautiously. A biopsy of morphea demonstrates squared-off edges and thick collagen, whereas eczema presents spongiotic dermatitis, for instance. Early scleroderma biopsies (mainly systemic) can lack specificity; therefore, clinical correlation is crucial. When uncertain, consult specialists early.

Pitfalls in Diagnosis

Diagnosing pediatric scleroderma is challenging because of its rarity and diverse presentation. Here are common pitfalls and strategies to avoid them:

Attributing skin changes to benign causes for too long: Dismissing a child’s skin lesion as a birthmark, eczema patch, or scar is easy. Many families report initial reassurance that the patch was “nothing serious.” In a Zurich cohort, none of 50 children with localized scleroderma were correctly diagnosed at first presentation to their primary doctor; 44% were given no diagnosis, and others were misdiagnosed as eczema (20%), nevus (8%), fungal infection (6%), bruise or vascular lesion. Pitfall: Watchful waiting for months or treating as eczema without improvement. Solution: If a skin lesion doesn’t respond to standard therapies or is evolving despite treatment, reconsider the diagnosis and refer. An enlarging, indurated lesion should not be continually treated as eczema beyond a few weeks without improvement – pursue further evaluation.

Neglecting to conduct a comprehensive skin examination in children with musculoskeletal issues is a critical oversight. A child might display a limp or stiff joint and subsequently be referred to an orthopedic specialist or physical therapy. However, if the child has undiagnosed linear scleroderma affecting the limb, the underlying cause, which involves tightening the skin and fascia, may go unrecognized. A common pitfall in this situation is overlooking a subtle linear lesion due to an examination focused primarily on the joints. The solution is to consistently perform a thorough skin examination in children with unexplained contractures, limb length discrepancies, or joint movement limitations. Pay particular attention to the areas involved for signs of morphea, which can sometimes be felt as a firm band, even if it isn’t visible discoloration).

Assuming that all Raynaud’s phenomenon in adolescents is “primary”: While it is accurate that most of Raynaud’s cases in teenagers, particularly girls, are benign and classified as primary, it is essential to remain alert for signs of secondary Raynaud’s. Pitfall: Ignoring Raynaud’s and neglecting to check for nailfold capillary alterations or ask about other symptoms. Solution: For every child or teenager presenting with Raynaud’s, assess for additional symptoms (such as finger swelling, joint pain, reflux, or skin tightening) and conduct a nailfold capillaroscopy when feasible or refer to a specialist. If capillary abnormalities are observed or ANA is positive, avoid labeling the case as primary Raynaud’s and promptly arrange a rheumatology evaluation.

Overdependence on serology: Negative antibody tests may provide false reassurance to clinicians. For instance, a child exhibiting clear linear scleroderma often presents with negative ANA levels and lacks other laboratory abnormalities. Relying solely on a “positive test” for diagnosis is a common mistake. Solution: Prioritize clinical findings for diagnosis. Similarly, a positive ANA result in a healthy child can lead to confusion since ANA positivity lacks specificity and may be transient or unrelated. It should complement, not override, clinical judgment. In juvenile systemic sclerosis (jSSc), most patients will test positive for ANA, but rare cases may be seronegative; therefore, a child displaying classic skin and organ symptoms should be treated as jSSc, even with negative antibody results.

Overlooking systemic aspects in “localized” scleroderma: Although morphea, by definition, does not affect internal organs, specific subtypes (such as linear craniofacial and generalized) can lead to extracutaneous symptoms (e.g., seizures, uveitis, arthritis). Pitfall: Treating morphea solely as a dermatological issue while neglecting underlying concerns. Solution: Implement a checklist for children with localized scleroderma that includes evaluations for limb length discrepancies, limited joint range of motion, neurological signs (e.g., headache, seizures if the scalp is involved), and ocular symptoms (like eye redness or vision changes due to facial lesions). Consensus guidelines recommend MRI for brain lesions associated with head involvement and ophthalmologic assessments for uveitis. Pediatricians should facilitate relevant screenings (such as ophthalmology) once any lesion is detected.

Delays in specialist referrals: Due to the rarity of scleroderma, doctors might take a “wait and see” stance or experience lengthy referral times. A survey of caregivers showed that the primary obstacle to receiving care was insufficient physician awareness, noting that in approximately 28% of cases, diagnosis exceeded one year from the initial symptoms. Each month lost in treating active disease can result in irreparable damage, such as the stunting of arm growth caused by untreated linear scleroderma over a year. Solution: Refer patients early if scleroderma is a potential diagnosis—even without a confirmed diagnosis, a pediatric rheumatologist or dermatologist can assist in further evaluation.

A potential issue in diagnosing systemic sclerosis is the confusion with other systemic diseases. For instance, a child showing signs of weight loss, GERD, and fatigue may be misdiagnosed with inflammatory bowel disease or anorexia, overlooking subtle skin tightening. Similarly, a child with a chronic cough and exercise intolerance might be referred to pulmonology and diagnosed with asthma. At the same time, the actual issue could be the onset of pulmonary fibrosis due to scleroderma. To avoid this, maintain a broad differential diagnosis. If several organ systems are affected (for example, gastrointestinal and skin or pulmonary and vascular), it’s essential to consider a possible underlying connective tissue disease. Simple screenings, such as assessing skin turgor in the fingers or inquiring about Raynaud’s phenomenon, can lead to a diagnosis that may not have been initially considered.

In summary, the biggest diagnostic pitfall is a lack of familiarity—many generalists may never have encountered a case during training. Awareness of the hallmark signs (indurated skin lesions, Raynaud’s with skin changes) and maintaining a low referral threshold can help address this issue. As one study highlighted, “lack of knowledge about juvenile scleroderma in the medical community” is a significant problem recognized by families. Acknowledging our blind spots and involving experts early can help avoid these pitfalls.

Typical Patient Pathways Until Diagnosis

Children with scleroderma often have a protracted journey before receiving the correct diagnosis. Understanding these typical pathways can help primary providers shorten the timeline:

Localized scleroderma (morphea) pathway: Parents or pediatricians may notice an unusual patch or streak on a child’s skin. The initial stop is often the primary care physician, where first impressions may be benign. Many are told it’s eczema or a fungal infection and are given topical treatments. Families might seek further assistance when the lesion doesn’t improve – or even enlarges. The next step is often a consultation with a dermatologist. In a study involving 50 children, the median time from disease onset to consulting a specialist was about 7.5 months. Dermatologists identified scleroderma in approximately two-thirds of cases during that first specialist visit. Some children left their initial dermatology visit without a diagnosis, as lesions were mistaken for conditions like port-wine stains or unusual scars, leading to further referrals. Many children end up at a pediatric rheumatology center, especially if the disease progresses. The total delay from onset to correct diagnosis averaged around 11 months in the Zurich cohort, and other studies similarly report an average delay of nearly one year. During this time, families often endure anxiety and frustration. A qualitative survey revealed that families struggled to find reliable information and faced long waits for specialist appointments. Practical point: As a pediatrician, if you suspect morphea, you can expedite this journey by directly referring to a center specializing in pediatric rheumatology or dermatology without waiting months for observation. Early referral not only leads to diagnosis but also to earlier initiation of treatment – a study found that over a third of patients waited more than a year to start systemic therapy after symptom onset, likely due to diagnostic delays. Taking swift action can reduce this wait time.

Systemic sclerosis pathway: Since jSSc is rare, the journey often involves multiple specialties. Initial symptoms may be vague, including Raynaud’s phenomenon, fatigue, hand stiffness, or reflux. The child might first consult a pediatrician or even a specialist like a cardiologist if they have unexplained pulmonary hypertension or a gastroenterologist if growth falters and reflux is prominent. It is not uncommon for the diagnosis of systemic sclerosis to be considered only after an organ complication has occurred. For example, a case might present to nephrology with ra enal crisis or to pulmonology with interstitial lung disease before skin changes are noted. Thankfully, such presentations are uncommon in children (the renal crisis is rare in jSSc). More often, puffy hands and Raynaud’s eventually lead someone to suspect a rheumatic disease. Many children with jSSc fulfill the criteria for an overlap syndrome, and their path may begin under another diagnosis (such as “atypical juvenile dermatomyositis” or “undifferentiated connective tissue disease”) until scleroderma fully manifests. Ultimately, pediatric rheumatology serves as the hub where these patients are diagnosed. The classification criteria used for adults (ACR/EULAR 2013) perform reasonably well in children – one study found that 83% of children met adult criteria (those who didn’t have overlap features). Once at a rheumatology center, an appropriate workup (capillaroscopy, autoantibody panel, organ function tests such as PFTs, echocardiogram, GI studies) is conducted to confirm jSSc and assess its extent. Families typically experience a “diagnostic odyssey” with jSSc, often consulting multiple doctors. A key observation is that pediatric rheumatology referrals tend to occur earlier when Raynaud is present, reflecting increased awareness. Nonetheless, given the rarity, many pediatricians will refer any child with refractory Raynaud’s or unusual skin findings to rheumatology as a precaution, which is appropriate even if it turns out not to be scleroderma.

Multidisciplinary involvement: Both conditions eventually require a team. It’s common for a child to see dermatologists, rheumatologists, neurologists, orthopedists, and rehabilitation specialists before and after diagnosis. For example, a child with en coup de sabre might see a neurologist for seizures, an ophthalmologist for an eye exam, and a dentist for jaw issues in addition to rheumatology. Sometimes, these various consultations happen before someone pieces together the unifying diagnosis of scleroderma. Primary care providers can help coordinate and ensure information is shared among specialists. Once diagnosed, the patient pathway includes regular follow-ups with rheumatology and often returns to the primary pediatrician for general health maintenance with guidance from the specialists on monitoring.

In Central Europe, specialized centers and networks (e.g., the PRES/SHARE network) streamline these pathways. For instance, the SHARE initiative has established recommendations to standardize care and likely has increased recognition across Europe. Primary care providers should feel empowered to connect with these networks by referring early – most pediatric rheumatologists would prefer to see a potential scleroderma case sooner rather than later, given the potential for harm associated with its delay.

Typical timeline (localized): Onset of skin lesion → (1-3 months) primary care visit (often misdiagnosed or observed) → (6-9 months) dermatology visit (diagnosis made in ~60% cases) → referral to rheumatology for treatment → (9-12 months from onset) treatment begins. Our aim should be to collapse this timeline, ideally getting treatment initiated within 3-6 months of disease onset. Educating school nurses, general pediatricians, and dermatologists about morphea can help, as they are often the first contacts.

Typical timeline (systemic): Onset of Raynaud’s or vague symptoms → primary care (basic labs, maybe ANA) → rheumatology referral (if the clue is Raynaud/ANA) OR other specialty (if presenting feature is organ-specific) → diagnosis at rheumatology after comprehensive evaluation. This timeline varies widely due to heterogeneity of presentation; some children are diagnosed within a few months if skin signs are apparent, while others may go a year or more being treated for individual organ problems before someone recognizes the systemic pattern. Key point: Any delay in diagnosis of jSSc can allow organ damage to accrue, so primary providers should always keep it in their differential when appropriate and ensure such patients reach a tertiary center promptly.

When to Involve Pediatric Rheumatologists

Pediatric rheumatology involvement is essential as early as possible in the diagnostic process for suspected scleroderma. Current consensus guidelines explicitly recommend referring any child with suspected scleroderma to a specialized pediatric rheumatology center without delay. This is because rheumatologists possess the expertise to confirm the diagnosis (through targeted history, exams like nailfold capillaroscopy, and coordinated investigations) and can initiate suitable therapy to prevent complications. Here are specific recommendations on when to involve pediatric rheumatology:

Immediately upon clinical suspicion: If you, as an outpatient pediatrician, notice features indicative of scleroderma (any scenario outlined in the “When to consider” section), it is advisable to refer the child to pediatric rheumatology immediately. You do not need to feel pressured to conclusively prove the diagnosis (for example, through biopsy or lab tests) before making a referral. The key principle from the European SHARE guidelines is that all children with suspected localized scleroderma should be referred to pediatric rheumatology. This reasoning also applies to suspected systemic sclerosis. Early evaluation by a specialist can confirm the diagnosis and initiate treatment during the critical window when it can most effectively improve outcomes.

If a child has confirmed localized scleroderma (morphea), even if a dermatologist makes the diagnosis through biopsy or clinical examination, it is important to involve a pediatric rheumatologist for management. Why? Localized scleroderma, particularly moderate to severe subtypes, often requires systemic therapy (such as methotrexate or systemic corticosteroids), which pediatric rheumatologists are skilled in administering. Co-management with dermatology is ideal, as dermatologists can assist with biopsies, topical adjuncts, and phototherapy; however, rheumatology should lead systemic immunosuppressive treatment and monitor for extracutaneous involvement. Refer at diagnosis, or if the diagnosis was made by dermatology, ensure a referral to rheumatology is established for therapy guidance. Mild, superficial plaque morphea might be managed by dermatology alone (using topicals and phototherapy), but any lesion that extends beyond superficial or any sign of spread warrants input from rheumatology according to guidelines.

If a child has confirmed or suspected systemic sclerosis, this is a rheumatologic emergency because specialized care is necessary for screening and managing organ involvement. Always involve pediatric rheumatology for systemic sclerosis; there is no scenario in which jSSc should be managed without a rheumatologist. In fact, pediatric rheumatology will coordinate a multidisciplinary approach involving cardiology for echocardiograms, pulmonology for lung function, nephrology if needed, and so on. If you encounter a child with a new diagnosis of systemic sclerosis (perhaps diagnosed by an adult rheumatologist or dermatologist due to the patient’s age being around 16), transferring or referring them to a pediatric rheumatology center is recommended because children have unique needs such as growth, development, school issues, and a different spectrum of organ features. Additionally, there are pediatric-specific consensus treatment plans, such as the jSSc SHARE protocol. Central Europe has pediatric rheumatology units commonly found in academic centers (for example, Semmelweis University in Budapest, which is one author affiliation in consensus reports); these are the appropriate hubs for jSSc.

Red flags requiring immediate referral: If a child with known localized scleroderma develops new concerning symptoms (e.g., seizures in a child with en coup de sabre, suggesting CNS involvement), or if a child with Raynaud’s shows any signs of digital ulcers or lung problems, these situations should prompt an urgent rheumatology evaluation instead of waiting for the next routine visit. Essentially, any indication that the disease is more extensive than previously believed should accelerate rheumatology involvement.

Role of pediatric dermatologists: While pediatric rheumatologists are central, pediatric dermatologists also play a crucial role, especially in diagnosis through skin biopsy and in managing skin-directed therapies such as topicals and phototherapy. Ideally, for localized scleroderma, the child should be seen by both a pediatric rheumatologist and a dermatologist, as many centers operate combined clinics for morphea. However, if initially only one specialist can be involved, the rheumatologist is preferred for systemic oversight and therapy initiation. They can then involve dermatology as needed. For systemic sclerosis, dermatology is less involved, except perhaps for skin ulcer care or cosmetic support, while rheumatology and other subspecialties, like pulmonology, are essential.

Diagnostic workup by rheumatologists: Pediatric rheumatologists conduct specialized assessments that general pediatricians typically do not, such as nailfold capillary microscopy, comprehensive autoantibody panels, and organ imaging (e.g., high-resolution CT for lungs if necessary). They also employ pediatric severity indices (e.g., LoSSI/LoSDI for localized scleroderma activity/damage scoring) to track disease progression. Early involvement allows for baseline measurements to be established and monitored to evaluate treatment response.

In practical terms, refer to pediatric rheumatology as soon as scleroderma appears in the differential diagnosis—this may involve sending the child to a tertiary center. The consensus-based practice in Europe is that early referral leads to the best outcomes. Pediatricians should also facilitate the involvement of other specialists through rheumatology. For instance, if linear scleroderma on the face is suspected, you might simultaneously refer to rheumatology and request an MRI of the brain along with an ophthalmology exam (as recommended), but ensure that the rheumatologist is informed and coordinating these efforts.

Family guidance: When making a referral, it’s helpful to prepare the family for the fact that multiple specialists will likely be involved. Emphasize that pediatric rheumatologists have experience with these rare diseases and will lead a team for their child. Sometimes, families are hesitant to travel or wait for a tertiary appointment. Explaining the importance (“this condition can affect not just skin but growth and organs, and a specialist needs to guide tests and treatment”) can improve adherence to the referral.

In summary, the early and proactive involvement of pediatric rheumatology is the standard of care for juvenile scleroderma. It has been shown to standardize and enhance management. For example, the SHARE initiative provided a Europe-wide protocol that pediatric rheumatologists follow for initiating methotrexate and systemic steroids in active localized scleroderma, which has led to improved outcomes. As an outpatient pediatrician, your role is to identify and promptly refer patients while providing ongoing supportive care, including monitoring growth, ensuring vaccinations, and managing intercurrent illnesses, in collaboration with the specialist team.

Management Overview and Recent Guidelines

While specialists will handle the detailed management of scleroderma in children, primary care providers should be informed about first-line treatments and current guidelines to educate families and co-manage general aspects. Here, we summarize the approach, focusing on practical points and recent consensus recommendations relevant to Central Europe:

Localized scleroderma (morphea) management aims to halt active inflammation and prevent irreversible fibrosis. For limited, superficial lesions, dermatologists can employ topical therapies, such as high-potency steroids or calcineurin inhibitors like tacrolimus, along with phototherapy (UVA1). However, for most cases of pediatric morphea beyond a small plaque, systemic treatment is necessary. Methotrexate (MTX) serves as the cornerstone of therapy; European consensus strongly endorses MTX (oral or subcutaneous, approximately 15 mg/m²/week) for active, disfiguring, or debilitating morphea. It is common to initiate MTX in conjunction with a short course of systemic corticosteroids to accelerate disease remission. For instance, a child with linear scleroderma affecting the leg may receive oral prednisone or IV pulse methylprednisolone for 3–6 months while MTX takes effect. After sufficient improvement, MTX is generally continued for a minimum of 12 months before tapering in order to ensure sustained remission. If MTX proves ineffective or is not tolerated, mycophenolate mofetil (MMF) is an alternative immunosuppressant according to consensus. Other treatments such as IV immunoglobulin, cyclosporine, or cyclophosphamide have been used in severe cases anecdotally; however, the evidence is limited. Although biologic agents are not yet standard for morphea, emerging small studies on abatacept or tocilizumab are being explored. Adjunct therapies, including physiotherapy (to maintain range of motion if joints or limbs are affected) and orthopedic interventions (such as shoe lifts for limb length discrepancy) can be implemented as needed. The most recent guidelines include the 2019 SHARE consensus, which is endorsed by PReS, providing a framework for assessment and treatment. Additionally, national guidelines like the updated 2016 German dermatology-rheumatology S2k guideline align with these recommendations, emphasizing the use of MTX plus systemic steroids as the first line for linear or generalized morphea. Pediatricians should ensure that patients on MTX are monitored for side effects (liver enzymes, blood counts); while this is typically managed by the rheumatologist, it’s important to check if interim labs are required during patient visits. Families should also be counseled on the long-term nature of treatment: a full course typically spans 2–3 years or more, with the first year being intensive. This approach helps set realistic expectations and enhances adherence.

Juvenile systemic sclerosis management is complex and always tailored to organ involvement. However, several principles from the recent EULAR/PReS consensus and expert guidance can be highlighted. Immunosuppression is key to controlling the fibrosing process. Methotrexate has been used for skin involvement in jSSc by extrapolation from adult trials that show some skin score improvement and may be prescribed, especially if there is significant cutaneous disease or arthritis. Mycophenolate mofetil is frequently used for lung and skin; in fact, current practice often utilizes MMF as a first-line treatment for jSSc lung involvement (interstitial lung disease) due to its efficacy in adults and better tolerance than cyclophosphamide. The recent 2022 international consensus from the Hamburg meeting suggests that combining MTX and MMF should be considered in refractory cases to achieve better control. Cyclophosphamide (IV pulses) is reserved for severe organ-threatening disease—such as progressive interstitial lung disease or myocardial involvement—and is generally a second-line option if MMF fails or as induction in very aggressive cases. After cyclophosphamide induction, patients are often switched to MMF for maintenance. Biologic therapies, though not yet standard, include options like tocilizumab (anti-IL6) and rituximab (anti-CD20), which have been used in juvenile SSc cases with some success in stabilizing skin and lung conditions. The 2022–2024 expert panel recommended considering the addition of a biologic (tocilizumab or rituximab) if there is an inadequate response after 6 months of conventional immunosuppressants. Interestingly, about 10% of children in an international cohort received tocilizumab within the first year of follow-up, reflecting an early adoption of this strategy in refractory cases. Hematopoietic stem cell transplant (HSCT) is a treatment of last resort for diffuse jSSc that is not controlled by other means. Adult trials (ASTIS, SCOT) showed that HSCT can significantly improve survival in severe diffuse SSc, and this approach is being carefully extended to pediatric cases. A recent consensus by EULAR and EBMT in 2023 provides guidance for considering HSCT in jSSc, generally for cases where the disease is rapidly progressive and life-threatening despite optimal therapy. Of course, these children would be treated at highly specialized centers. Symptomatic and supportive care is crucial: for Raynaud’s, almost all children are placed on vasodilators such as calcium channel blockers (nifedipine) and advised to keep warm; for GI reflux, proton-pump inhibitors are used liberally; for musculoskeletal pain or contractures, early implementation of physical therapy and occupational therapy (including splinting and stretching) is recommended. Avoiding triggers like cold exposure (for Raynaud’s) and trauma (to prevent calcinosis or ulcers) is emphasized. Pediatric rheumatologists also monitor for and treat complications like pulmonary hypertension, often in collaboration with cardiology using endothelin receptor antagonists or phosphodiesterase-5 inhibitors.

Vaccinations and infections: Children on immunosuppressants (MTX, MMF, biologics) should receive inactivated vaccines according to schedule. Live vaccines are generally avoided during high-dose immunosuppression, but each case is individual—consult the rheumatologist. An annual influenza vaccine is recommended. Pediatricians should remain vigilant for infections (zoster can occur in those on chronic steroids or MMF, for example) and communicate with rheumatology if major infections arise (therapy may need adjustment).

Growth, nutrition, and psychosocial support: Chronic illness and medications can impact growth and mood. Ensure that the child’s growth parameters are monitored; involve nutritionists if intake is a concern (especially in jSSc, where esophageal involvement may lead to malnutrition). Psychosocially, these conditions can be isolating due to cosmetic changes and the rarity of the disease. Referring to patient support groups (including scleroderma family networks, some facilitated by rheumatology associations) can be beneficial. School accommodations might be necessary (for example, extra time to write if hand mobility is limited, protection from cold exposure during school activities for Raynaud’s, etc.). Pediatric rheumatologists often provide medical letters to support such accommodations, but the pediatrician can also reinforce them with the school.

Central European context: The latest guidelines relevant to Central Europe originate from both Europe-wide initiatives and national societies. The EULAR (European Alliance of Associations for Rheumatology) 2016 recommendations for adult SSc management, updated in 2023, provide a framework for organ-based treatment (e.g., ACE inhibitors for scleroderma renal crisis, bosentan for digital ulcer prevention). Pediatric rheumatologists adapt these guidelines for children, recognizing differences (for instance, the renal crisis is extremely rare in jSSc, but the principle of monitoring blood pressure and prompt ACE inhibitor use if necessary still applies). The PReS/SHARE initiative (Single Hub and Access Point for Pediatric Rheumatology in Europe) produced consensus treatment plans for jSSc in 2017 and for localized scleroderma in 2019. These plans have been disseminated among European pediatric rheumatologists, thus standardizing care. Furthermore, countries like Germany have published interdisciplinary guidelines (e.g., the 2017 update on “Diagnostik und Therapie der zirkumskripten Sklerodermie” in Dermatologie und Kinder-Rheumatologie) that reflect these consensus statements. The British Society for Rheumatology 2022 guideline for SSc also emphasizes the importance of early diagnosis and includes considerations for juveniles. Pediatricians in Central Europe should be aware that these resources are available, indicating that if they refer a patient, the receiving specialist will likely adhere to a protocol that is evidence-informed and supported by consensus. 

For primary care, key reference points include the SHARE recommendations (Ann Rheum Dis 2019 for JLS; Rheumatology (Oxford) 2021 for jSSc) and review articles, such as the 2023 “Morphea update,” which concisely cover the current understanding of diagnosis and management, along with the 2024 expert panel guidance on jSSc. These resources can be consulted for deeper knowledge or when co-managing aspects of care.

In conclusion, pediatric scleroderma requires a high level of suspicion for diagnosis and a collaborative approach to management. Outpatient pediatricians play a crucial role in early recognition—observing the key clinical signs and not dismissing them—and in referring patients early to pediatric rheumatology. By understanding the differential diagnoses and potential pitfalls, primary providers can avoid delays that have historically plagued scleroderma care. Once diagnosed, familiarity with general management principles (immunosuppression, therapy duration, multidisciplinary needs) enables the pediatrician to support the child and family through what is often a lengthy journey. With improved awareness and adherence to consensus guidelines, outcomes for children with scleroderma are improving: recent data suggest that juvenile systemic sclerosis has a significantly better 10-year survival rate (~98%) compared to adult-onset disease (~75%), likely due to proactive treatment. Similarly, timely therapy in localized scleroderma can prevent the permanent disabilities that were once commonly seen. By remaining alert to the signs of scleroderma and engaging rheumatology colleagues early, primary care pediatricians in Central Europe and worldwide can ensure that these rare patients receive the specialized care they need as soon as possible.

References: (Key guidelines and studies supporting the above information)

Zulian F, et al. Ann Rheum Dis. 2019;78(8):1019-1024 – SHARE Consensus on Juvenile Localized Scleroderma (European multi-expert recommendations on diagnosis and management).

Foeldvari I, et al. Rheumatology (Oxford). 2021;60(4):1651-1658 – Consensus-based recommendations for management of juvenile systemic sclerosis (PReS SHARE initiative).

Jacquel L, et al. Pediatr Rheumatol. 2025;23:13 – Updated French cohort of Juvenile SSc (overview of presentation and outcomes, incidence data).

Martini G, Foeldvari I, et al. Pediatr Rheumatol. 2018;16(1):9 – Delay in diagnosis of juvenile localized scleroderma (highlights misdiagnoses and referral delays).

Kreuter A, et al. J Dtsch Dermatol Ges. 2016;14(2):199-216 – German S2k Guideline on Localized Scleroderma (in German; English summary emphasizes classification and MTX treatment) .

Steen VD, et al. Arthritis Rheum. 2013;65(10):2737-47 – ACR/EULAR Classification Criteria for SSc 2013 (adult criteria often applied in pediatrics, mentioned for context).

Torok KS, et al. Arthritis Care Res. 2012;64(2):219-33 – Pediatric localized scleroderma damage index (LoSDI) and activity index (LoSSI) (tools for assessment, referenced in SHARE guidelines).

Denton CP, et al. Ann Rheum Dis. 2024 (epub) – EULAR 2023 Update on SSc Management (adult guideline update, informs organ-based management applied to pediatrics).

Foeldvari I, et al. Expert Rev Clin Immunol. 2024;20(4):387-404 – International Consensus 2022 (Hamburg) on jSSc Treatment (latest expert guidance, e.g. combining MMF+MTX, biologics, HSCT).

DermNet NZ – Morphoea (2022). Accessible clinical summary of localized scleroderma for practitioners.